Serotonin in migraine: Theories, animal models and emerging therapies

Progress in Drug Research

Volumn 51, Issue , 1998, Pages 219-244

  Johnson, Kirk W ^a,b   Phebus, Lee A ^a,c,d,e   Cohen, Marlene L ^a,d,e,f,g  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c CLARK UNIVERSITY   (United States)

^d INDIANA UNIVERSITY   (United States)

^e Lilly Research Laboratories

^f University of California

^g Roche Institute of Molecular Biology

Author keywords

5 HT(1B) receptor, 5 HT(1D) receptor, 5 HT(1F) receptor, 5 HT(2B) receptor; Animal models; Calcitonin gene related peptide; Clinical therapies; Dural protein extravasation; Migraine; Neurogenic inflammation; Nitric oxide; Review; Serotonin; Serotonin agonists; Serotonin antagonists; Substance P

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 4,5,7A,8,9,10,11,11A OCTAHYDRO 10 METHYL 7H INDOLO[1,7 BC][2,6]NAPHTHYRIDINE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; ALMOTRIPTAN; ALNIDITAN; AVITRIPTAN; BMS 181885; CALCITONIN GENE RELATED PEPTIDE; DIHYDROERGOTAMINE; ELETRIPTAN; GLYCERYL TRINITRATE; LY 266097; LY 272015; LY 334864; METHYSERGIDE; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; N [4 [5 [3 (2 AMINOETHYL) 1H INDOL 5 YL] 1,2,4 OXADIAZOL 3 YL]BENZYL]METHANESULFONAMIDE; NARATRIPTAN; RIZATRIPTAN; SEROTONIN 1 AGONIST; SUBSTANCE P; SUMATRIPTAN; UK 116004; UNCLASSIFIED DRUG; XYLAMIDINE; ZOLMITRIPTAN;

BRAIN NERVE CELL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; ELECTROSTIMULATION; FATIGUE; HEADACHE; HUMAN; MIGRAINE; MYALGIA; NEUROGENIC INFLAMMATION; ONCOGENE C FOS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SENSORY NERVE CELL; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; SOMNOLENCE; TREATMENT PLANNING; VASODILATATION; VERTIGO;

EID: 0031785357     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0348-8845-5_6     Document Type: Review

References (123)

1. Sicuteri F., Testi A. and Anselmi B.: Int. Arch. Allergy 19, 55-58 (1961).
2. Curran D.A., Hinterberger H. and Lance J.W.: Brain 88, 997-1007 (1965).
3. Anthony M., Hinterberger H.J. and Lance J.W.: Arch. Neurol. 16, 544-552 (1967).
4. Ferrari M.D., Odink J., Tapparelli C., Van Kempen G.M.J., Pennings E.S.M. and Bruyn G.W.: Neurology 39, 1239-1242 (1989).
5. Fozard J.R.: Prog. Pharmacol. 4, 135-146 (1982).
6. Griffith S.C. and Burnstock G.: Lancet 1, 561-562 (1983).
7. Carroll J.D. and Hilton B.T.: Headache 14, 149-156 (1974).
8. Del Bene E., Anselmi B., Del Bianco P.L., Fanciullacci M., Gali P., Salmon S. and Sicuterri F., in: F. Sicuteri (ed.): Headache, new vistas. Biomedical Press, Florence 1977, pp. 101-109.
9. Graham J.R. and Wolff H.G.: Arch. Neurol. Psychia. 39, 737-763 (1938).
10. Nichols F.T., Mawad M. and Mohr J.P.: Stroke 21, 555-559 (1990).
11. Dahl A., Russell D., Nyberg-Hansen R. and Rootwelk K.: Cephalalgia 10, 87-94(1990).
12. Kimball R., Friedman A. and Vallejo E.: Neurology 10, 107-111 (1960).
13. Saxena P.R., in: J.N. Blau (ed.): Migraine - therapeutic, conceptual and research aspects. Elsevier, Amsterdam 1987, pp. 581-596.
14. Saxena P.R., in: J. Olesen and M.A. Moskowitz (eds.): Experimental headache models in animal and man. Lippincott-Raven Publishers, Philadelphia 1995, 189-198.
15. Andersen A.R., Freiberg L., Olsen T.S. and Olesen J.: Arch. Neurol. 45, 154-159 (1988).
16. Ferrari M.D., Haan J., Blokland J.A.K., Arndt J.W., Minnee P., Zwinderman A.H., Pauwels E.K.J. and Saxena P.R.: Arch. Neurol. 52, 135-139 (1995).
17. Zwetsloot C.P., Caekebeke J.F.V. and Jansen J.C.: Cephalalgia 11, 103-107 (1991).
18. Zwetsloot C.P., Caebeke J.F.V. and Ferrari M.D.: Stroke 24, 1335-1338 (1993).
19. Olsen J. and Paulson O.B.: Stroke 2, 148-159 (1971).
20. Wei E.P., Moskowitz M.A., Boccalini P. and Kontos H.A.: Circ. Res. 70, 1313-1319 (1992).
21. Goadsby P.J. and Edvinsson L.: Ann. Neurol. 33, 48-56 (1993).
22. Moskowitz M.A.: Trends Pharmacol. Sci. 13, 307-311 (1992).
23. Pearce J.M.S.: Lancet 2, 86-89 (1984).
24. Moskowitz M.A., Nozaki K. and Kraig R.P.: J. Neurosci. 13, 1167-1177 (1993).
25. Moskowitz M.A.: Neurology 43, S 16-20 (1993).
26. Markowitz S., Saito K. and Moskowitz M.A.: J. Neurosci. 7, 4129-4136 (1987).
27. Moskowitz M.A.: Neurology 41, 182-186 (1991).
28. Ray B.S. and Wolff H.G.: Arch. Surg. 41, 813-856 (1940).
29. Goadsby P.J., Zagami A.S. and Lambert G.A.: Headache 31, 365-371 (1991).
30. Goadsby P.J., Edvinsson L. and Ekman R.: Ann. Neurol. 23, 193-196 (1988).
31. Moskowitz M.A., Lee W.S. and Cutrer F.M., in: P. Geppetti and P. Holzer (eds.): Neurogenic Inflammation, CRC Press, New York 1996, 187-199.
32. Beattie D.T., McNeil D.K. and Connor H.E.: Neuropeptides 213, 228-230 (1993).
33. Dimitriadou V., Buzzi M.G., Moskowitz M.A. and Theoharides T.C.: Neuroscience 44, 97-112 (1991).
34. Dimitriadou V., Buzzi M.G., Theoharides T.C. and Moskowitz M.A.: Neuroscience 48, 187-203 (1992).
35. Brain S.D. and Williams T.J.: Br. J. Pharmacol. 86, 855-860 (1985).
36. Le Greves P., Nyberg F., Terenius L. and Hokfelt T.: Eur. J. Pharmacol. 115, 309-311 (1985).
37. Olesen J., Thomsen L.L. and Iversen H.K.: Trends Pharmacol. Sci. 15, 149-153 (1994).
38. Olesen J., Inversen H.K. and Thomsen L.L.: Neuroreport 4, 1027-1030 (1993).
39. Thomsen L.L., Kruuse C., Iversen H.K. and Olesen J.: Eur. J. Neurol. 1, 73-80 (1994).
40. Lassen L.H., Ashina M., Christiansen I., Ulrich F. and Olesen J.: Lancet 349, 401-402 (1997).
41. Fozard J.R.: Arch. Int. Pharmacodyn. 329, 111-119 (1995).
42. Jeffrey S.R. and Snyder S.H.: Ann. Rev. Cell Dev Biol. 11, 417-440 (1995).
43. Schmuck K., Ullmer C., Kalkman H.O., Probst A. and Lubbert H.: Eur. J. Neurosci. 8, 959-967 (1996).
44. Humphrey P.P., Feniuk W., Perren M.J., Connor H.E., Oxford A.W., Coates L.H. and Butina D.: Br. J. Pharmacol. 94, 1123-1132 (1988).
45. Humphrey P.P., Feniuk W., Perren M.J., Connor H.E. and Oxford A.W.: Cephalalgia Suppl. 9, 23-33 (1989).
46. Peroutka S.J. and McCarthy B.G.: Eur. J. Pharmacol. 163, 133-136 (1989).
47. Humphrey P.P., Feniuk W. and Perren M.J.: Headache 30, 12-16 (1990).
48. Deliganis A.V. and Peroutka S.J.: Headache 336, 228-231 (1991).
49. Weinshank R.L., Zgombick J.M., Macchi M.J., Branchek T.A. and Hartig P.R.: Proc. Natl. Acad. Sci. USA 89, 3630-3634 (1992).
50. Adham N., Kao H.T., Schecter L.E., Bard J., Olsen M., Urquhart D., Durkin M., Hartig P.R., Weinshank R.L. and Branchek T.A.: Proc. Natl. Acad. Sci. USA 90, 408-412 (1993).
51. Pascual J., Arco C.D., Romon T., Olmo E.D. and Pazos A.: Eur. J. Pharmacol. 295, 271-274 (1996).
52. Bouchelet I., Cohen Z., Case B., Seguela P. and Hamel E.: Mol. Pharmacol. 50, 219-223 (1996).
53. Johnson K.W., Schaus J.M., Durkin M.M., Audia J.E., Kaldor S.W., Flaugh M.E., Adham N., Zgombick J.M., Cohen M.L., Branchek T.A. and Phebus L.A.: NeuroReport 8, 2237-2240 (1997).
54. Cohen M.L., Johnson K.W., Schenck K.W. and Phebus L.A.: Cephalalgia 17, 631-638 (1997).
55. Willett F., Curven N., Adams J. and Armitage M.: Br. Med. J. 304, 1415 (1992).
56. Hillis W.S. and MacIntyre P.D.: Lancet 341, 1564-1565 (1993).
57. Ottervanger J.P., Paalman H.J., Boxma G.L. and Stricker B.H.: Lancet 341, 861-862 (1993).
58. Kalkman H.O.: Life Sci 54, 641-644 (1994).
59. Johnson K.W., Nelson D.L., Wainscott D.B., Lucaites V.L. and Phebus L.A.: Cephalalgia 17, 342 (1997).
60. Meyer J.S, Hata T. and Miai A., in: J.N. Blau (ed.): Migraine - therapeutic, conceptual and research aspects. Elsevier, Amsterdam 1987, pp. 265-302.
61. Heyck H.: Res. Clin. Stud. Headache 22, 1-28 (1969).
62. Saxena P.R. and Verdouw P.D.: J. Physiol. (Lond.) 332, 501-520 (1982).
63. Saxena P.R., DeVries P., Heiligers J.P.C., VanDenBrink A.M., Bax W.A., Barv T. and Wikstrom H.: Eur. J. Pharmacol. 312, 53-62 (1996).
64. Saxena P.R., VanDenBrink A.M., Heiligers J.P.C., Scalbert E. and Lemaitre B.G.: Pharmacol. & Toxicol. 79, 199-204 (1996).
65. Saxena P.R., DeBriew P., Wang W., Heiligers J.P.C., VanDenBrink A.M., Bax W.A. and Yocca F.D.: Naunyn Schmiedeberg's Arch. Pharmacol. 355, 295-302 (1997).
66. Perren M.J., Feniuk W. and Humphrey P.P.A.: Cephalalgia 9S, 41-46 (1989).
67. Buzzi M.G. and Moskowitz M.A.: Br. J. Pharmacol. 99, 202-206 (1990).
68. Connor H.E., Feniuk W. and Beattie D.T.: Cephalalgia 17, 145-152 (1997).
69. Martin G.R., Robertson A.D., MacLennan S.J., Prentice D.J., Barrett V.J., Buckingham J., Honey A.C., Giles H. and Moncada S.: Br. J. Pharmacol. 121, 157-164 (1997).
70. Brewerton T.D., Murphy D.L., Mueller E.A. and Jimmerson D.C.: Clin. Pharmacol. Ther. 43, 605-609 (1988).
71. Fuller R.W., Kurz K.D., Mason N.R. and Cohen M.L.: Eur. J. Pharmacol. 125, 71-77 (1986).
72. Nelson D.L., Wainscott D.B., Lucaites V.L., Calligaro D.O., Zgombick J.M., Audia J.E., Phebus L.A., and Johnson K.W.: Cephalalgia 17, 341-342 (1997).
73. Nozaki K., Boccalini P. and Moskowitz M.A.: Neurosci. 49, 669-680 (1992).
74. Nozaki K., Moskowitz M.A. and Boccalini P.: Br. J. Pharmacol. 106, 409-415 (1992).
75. Kaube H., Keay K.A., Hoskin K.L., Bandler R. and Goadsby P.J.: Brain Res. 629, 95-102 (1993).
76. Shepheard S.L., Williamson D.J., Williams J., Hill R.G. and Hargreaves R.J.: Neuropharmacol. 34, 255-261 (1995).
77. Buzzi M.G., Sajas D.E. and Moskowitz M.A.: Eur. J. Pharmacol. 165, 251-258 (1989).
78. Buzzi M.G., Moskowitz M.A., Peroutka S.J. and Byun B.: Br. J. Pharmacol. 103, 1421-1428 (1991).
79. Curtin T., Brooks A.P. and Roberts J.A.: Br. Med. J. 305, 713-714 (1992).
80. Luman W. and Gray R.S.: Lancet 341, 1091-1092 (1993).
81. Cavazos J.E., Caress J.B., Chilukuri V.R., Devlin T., Gray L. and Hurwitz B.J.: Lancet 343, 1105-1106 (1994).
82. Cady R.K., Wendt J.K., Kirchner J.R., Sargent J.D., Rothrock J.F. and Skaggs H.: JAMA 165, 2831-2835 (1991).
83. Tfelt-Hansen P.: Cephalalgia 13, 238-244 (1993).
84. Dahlof C., in: J. Olese (ed.): Frontiers in Headache Research Vol 6. Headache Treatment Trial Methodology and New Drugs. Lippencott-Raven Publishers, Philadelphia 1997, pp. 243-251.
85. Bates D., Ashford E., Dawson R., Ensink F.B., Gilhus N.E., Olesen J., Pilgrim A.J. and Shevlin P.: Neurol. 44, 1587-1592 (1994).
86. Phebus L.A., Johnson K.W., Zgombick J.M., Gilbert P.J., VanBelle K., Mancusco V., Nelson D.L.G., Calligaro D.O., Kiefer A.D., Branchek T.A. and Flaugh M.E.: Life Sci. 61, 2117-2126 (1997).
87. Yu X.J., Waeber C., Castanon N., Scearce K., Hen R., Macor J.E., Chauveau J. and Moskowitz M.A.: Mol. Pharmacol. 49, 761-765 (1996).
88. Forbes I.T., Kennet G.A., Gadre A., Ham P., Hayward C., Martin J., Thompson R.T., Wood M., Baxter M.D., Glen G.S., Murphy O.E., Steward B.R. and Blackburn T.P.: J. Med. Chem. 36, 1104 (1993).
89. Forbes I.T., Ham P., Booth D.H., Martin R.T., Thompson M., Baxter G.S., Blackburn T.P., Glen A., Kennett G.A. and Wood M.D.: J. Med. Chem. 38, 2524-2530 (1995).
90. Forbes I.T., Jones G.E., Murphy O.E., Holland V. and Baxter G.S.: J. Med. Chem. 38 (6), 855-857 (1995).
91. Bonhaus D.W., Bach C., DeSouza A., Salazar F.H.R., Matsuoka B.D., Zuppan P., Chan H.W. and Eglen R.M.: Br.J. Pharmacol. 115, 622-628 (1995).
92. Thomas D.R., Baxter G.S., Carey J.E., Gager T.L., Gale D.G., Holland V., Muir A., Wilson S. and Wood M.D.: Br.J. Pharmacol. 117, 137P (1996).
93. Nozulak J., Kalkman H.O., Floersheim P., Hoyer D., Schoeffler P. and Buerki H.R.: J. Med. Chem. 38, 28-33 (1995).
94. Cohen M.L., Audia J. and Nelson D.: ID Research Alert-Serotonin 2, 1-5 (1997).
95. Cohen M.L., Schenck K.W., Mabry T.E., Nelson D.L. and Audia J.E.: J. Serotonin Res. 3, 131-144 (1996).
96. Leysen J.E., Gommeren W., Heylen L., Luyten W.H.M.L., Van De Weyer I., Vanhoenacker P., Haegeman G., Schotte A., Van Gompel P., Wouters R. and Lesage A.S.: Mol. Pharmacol. 50, 1567-1580 (1996).
97. Domenech T., Beleta J. and Palacios J.M.: Naunyn Schmiedebergs Arch. Pharmacol. 356, 328-334 (1997).
98. Wurch T., Cathala C., Palmier C., Valentin J.P., John G.W., Colpaert F.C. and Pauwels P.J.: Neurosci. Res. Comm. 18, 155-162 (1996).
99. Wurch T., Palmier C., Colpaert F.C. and Pauwels P.J.: J. Neurochem. 68, 410-418 (1997).
100. Yocca F.D., Buchanan J., Gylys J.A., Hamel E., Iben L.G., Izzarelli D.G., Mahle C.D., Myers R., Noonan J.W., Parker E.M., Williams A.D., Sarbin N., Saxena P., Smith D.W. and Wiener H.L.: Cephalalgia 15, 174 (1995).
101. Gupta P., Napier C.M., Scatchard J., Shepperson N.B. and Wallis R.: Cephalalgia 17, 413 (1997).
102. Yocca F.D., Gylys J.A., Smith D.W., Ruediger E., Yevich J.P., Mahle C., Wiener H., Marcus R., Smith J., Saxena P. and Moskowitz M.: Cephalalgia 17, 404 (1997).
103. The Subcutaneous Sumatriptan International Study Group (1991): N. Engl. J. Med. 325, 316-321.
104. Fowler P.A., Lacey L.F., Thomas M., Keene O.N., Tanner R.J.N., and Baber N.S.: Eur. Neurol. 31, 291-294 (1991).
105. Cady R.K., Rubino, J., Crummett D. and Littlejohn III T.W.: Arch. Fam. Med. 3 (9), 766-772 (1994).
106. Sheftell F.D., Weeks R.E., Rapoport A.M., Siegel S., Baskin S. and Arrowsmith F.: Headache 34, 67-72 (1994).
107. Lloyd K.: Eur. Neurol. 34, 40-43 (1994).
108. 1 receptor agonists in the acute treatment of migraine. Clinical, epidemiological and pharmacological aspects. Eburon-Delft, Delft 1996.
109. Ferrari M.D., James M.H., Bates D., Pilgrim A.J., Ashford E.A., Anderson B. and Nappi G.: Cephalalgia 14, 330-338 (1994).
110. Ferrari M.D., Martin G.R., Earl N.L. and Klein K.B.: Eur. Neurol. 36 (Suppl2), 19-23 (1996).
111. Zagami A.S.: Neurology 48 (3), S25-S28 (1997).
112. Solomon G.D., Cady R.K., Klapper J.A., Earl N.L., Saper J.R. and Ramadan N.M.: Neurology 49 (5), 1219-1225 (1997).
113. Gunasekara N.S. and Wiseman, L.R.: CNS Drugs 8 (5), 402-408 (1997).
114. Gijsman H., Kramer M.S., Sargent J., Tuchman M., Matzura-Wolfe D., Polis A., Teall J., Block G. and Ferrari M.D.: Cephalalgia 17 (6), 647-651 (1997).
115. Sciberras D.G., Polvina W.J., Gertz B.J., Cheng H., Stepanavage M., Wittreich J., Olah T., Edwards M. and Mant T.: Br. J. Clin. Pharamcol. 43, 49-54 (1997).
116. Visser W.H., Terwindt G.M., Reines S.A., Jiang K., Lines C.R. and Ferrari M.D.: Arch Neurol. 53 (11), 1132-1137 (1996).
117. Schoen J.: Curr. Opin. Neurol. 10, 237-243 (1997).
118. Jackson N.C. for the Eletriptan Steering Committee: Cephalalgia 16, 368 (1996).
119. Cabarrocas X. and Salva M.: Cephalalgia 17, 421 (1997).
120. Goldstein J., Schellens R., Diener H.C., Dahlof C., Olesen J., Senard J.M., Steiner T.J. and Simard D., in: J. Olesen, P. Tfelt-Hansen (eds.): Headache treatment, trial methodology and new drugs. Lippincott-Raven Publishers, Philadelphia 1997, pp. 279-285.
121. Diener H.C., Gendolla A., Juptner M., Kaube H. and Limmroth V.: Eur Neurol. 38, 167-174 (1997).
122. Mathew N.T., in: N.T. Mathew (ed.): Advances in Headache. W.B. Saunders Company, Philadelphia 1997, vol. 15(1), 61-83.
123. Winner P., Ricalde O., Le Force B., Saper J., and Margul B.: Arch. Neurol. 53, 180-184 (1996).